Received May 26, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
Blisters; pain in hands/pain in feet; This non-serious case was reported by a physician via sales rep and described the occurrence of blister in a female patient who received Herpes zoster (Shingrix) for prophylaxis. On 17-APR-2025, the patient received the 1st dose of Shingrix. On 07-MAY-2025, 20 days after receiving Shingrix, the patient experienced blister (Verbatim: Blisters) and pain in extremity (Verbatim: pain in hands/pain in feet). The outcome of the blister and pain in extremity were not resolved. The reporter considered the blister and pain in extremity to be related to Shingrix. The company considered the blister and pain in extremity to be related to Shingrix. Additional Information: GSK receipt date: 21-MAY-2025 The physician reported that the patient had received 1st dose of Shingrix vaccine and experienced blisters and pain on hands and feet. The reporter mentioned that blister and pain on hands and feet was reported as worsened. The expiry date of Shingrix was unknown. This case had been link with US2025063517, reported by the same reporter.; Sender's Comments: US-GSK-US2025063517:same reporter